Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Luz Hammershaimb"'
Autor:
John E. Janik, Thomas A. Waldmann, Luz Hammershaimb, Karen Kaucic, Dirk Reitsma, Paul S. Albert, Mark Raffeld, Stefania Pittaluga, Thomas Fleisher, Margaret R. Brown, Helen Matthews, Maryalice Stetler-Stevenson, John C. Morris, Deirdre O'Mahony
Translation on this Article from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8503f7c52a990afce6ce287288e5ed31
https://doi.org/10.1158/1078-0432.22440441.v1
https://doi.org/10.1158/1078-0432.22440441.v1
Autor:
John E. Janik, Thomas A. Waldmann, Luz Hammershaimb, Karen Kaucic, Dirk Reitsma, Paul S. Albert, Mark Raffeld, Stefania Pittaluga, Thomas Fleisher, Margaret R. Brown, Helen Matthews, Maryalice Stetler-Stevenson, John C. Morris, Deirdre O'Mahony
Purpose: We report an increased incidence of EBV-induced B-cell lymphoproliferative disease (LPD) in patients treated with siplizumab, an anti-CD2 antibody. The development of EBV-LPD has been associated with the use of immunosuppressive agents used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ac91bb7565e1e40c0a53634257bdd81
https://doi.org/10.1158/1078-0432.c.6517770.v1
https://doi.org/10.1158/1078-0432.c.6517770.v1
Autor:
John E. Janik, Thomas A. Waldmann, Luz Hammershaimb, Karen Kaucic, Dirk Reitsma, Paul S. Albert, Mark Raffeld, Stefania Pittaluga, Thomas Fleisher, Margaret R. Brown, Helen Matthews, Maryalice Stetler-Stevenson, John C. Morris, Deirdre O'Mahony
Supplementary Tables S1-S3 from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df4eabde20104a650691e9673ca704c1
https://doi.org/10.1158/1078-0432.22440444.v1
https://doi.org/10.1158/1078-0432.22440444.v1
Autor:
Manuela Buzoianu, David A. Tice, Wenjun Wang, Uma N. M. Rao, John M. Kirkwood, Drazen M. Jukic, Stergios J. Moschos, LuAnn McKinney, Laura M Drogowski, Charalambos N. Athanassiou, Laura K. Richman, Shelley L. Reppert, Joel Leininger, Cindy Sander, Maja Mandic, Luz Hammershaimb
Publikováno v:
Journal of Immunotherapy. 33:316-325
AlphaVbeta3 (alphavbeta3) is an important molecule for tumor-induced angiogenesis and is upregulated in metastatic melanoma (MM). We proposed to study the mechanism of action of etaracizumab, a monoclonal antibody targeting alphavbeta3, in MM. Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4310665ab000895be2fd02a6d504839
https://doi.org/10.1097/cji.0b013e3181c1f216
https://doi.org/10.1097/cji.0b013e3181c1f216
Autor:
Jon M. Richards, Robert Weber, Jeffrey A. Sosman, Peter Hersey, William H. Sharfman, John M. Kirkwood, Manuela Buzoianu, Agop Y. Bedikian, Steven J. O'Day, Luz Hammershaimb, Rene Gonzalez, Theodore F. Logan
Publikováno v:
Cancer. 116:1526-1534
BACKGROUND: The alpha v beta 3 (αvβ3) integrin is involved in intracellular signaling regulating cell proliferation, migration, and differentiation and is important for tumor-induced angiogenesis. METHODS: This phase 2, randomized, open-label, 2-ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba3ab376b3219d507c42e00e46ca94a9
https://doi.org/10.1002/cncr.24821
https://doi.org/10.1002/cncr.24821
Autor:
John E. Janik, Maryalice Stetler-Stevenson, Helen F. Matthews, John C. Morris, Dirk Reitsma, Mark Raffeld, Luz Hammershaimb, Margaret R. Brown, Thomas A. Fleisher, Stefania Pittaluga, Deirdre O'Mahony, Thomas A. Waldmann, Paul S. Albert, Karen Kaucic
Publikováno v:
Clinical Cancer Research. 15:2514-2522
Purpose: We report an increased incidence of EBV-induced B-cell lymphoproliferative disease (LPD) in patients treated with siplizumab, an anti-CD2 antibody. The development of EBV-LPD has been associated with the use of immunosuppressive agents used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edcbfa5df9ae989611b21ee674ff86b5
https://doi.org/10.1158/1078-0432.ccr-08-1254
https://doi.org/10.1158/1078-0432.ccr-08-1254
Autor:
Karina Vera, Sandrine Faivre, Karen Kaucic, Luz Hammershaimb, Michel Marty, Eric Raymond, Catherine Delbaldo, Stéphanie Lozahic
Publikováno v:
Investigational New Drugs. 26:35-43
This study assessed the safety, immunogenicity, and pharmacokinetics of etaracizumab, a monoclonal antibody directed against the alphavbeta3 integrin, in patients with advanced malignancies. Four cohorts of four patients received escalating dose of e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38e8e850cd735deb399968766d662978
https://doi.org/10.1007/s10637-007-9077-0
https://doi.org/10.1007/s10637-007-9077-0
Autor:
Jin Soo Lee, Vincent A. Miller, Everett E. Vokes, David R. Gandara, Melvin Moore, Francis Gamza, Frank Dunphy, Jeffrey Crawford, Luz Hammershaimb, Daniel D. Karp, Ronald R. Natale, Frank V. Fossella, Russell F. DeVore, Yong Kim, Ronald N. Kerr, Mark G. Kris, L A Kalman
Publikováno v:
Journal of Clinical Oncology. 18:2354-2362
PURPOSE: To confirm the promising phase II results of docetaxel monotherapy, this phase III trial was conducted of chemotherapy for patients with advanced non–small-cell lung cancer (NSCLC) who had previously failed platinum-containing chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a694657a4414c1dc9da96fa7b264fbc
https://doi.org/10.1200/jco.2000.18.12.2354
https://doi.org/10.1200/jco.2000.18.12.2354
Autor:
Frederick L. Moffat, Yehuda Z. Patt, Luz Hammershaimb, David M. Goldenberg, Kevin S. Hughes, Nicholas J. Petrelli, Carl M. Pinsky
Publikováno v:
Annals of Surgery. 226:621-631
OBJECTIVE: The objective was to determine the role of arcitumomab (CEA-Scan; Immunomedics, Morris Plains, NJ), an anticarcinoembryonic antigen (CEA) Fab' labeled with technetium-99m, in the presurgical evaluation of patients with recurrent or metasta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fe23f7712567a3955678e0313f2a6aa
https://doi.org/10.1097/00000658-199711000-00007
https://doi.org/10.1097/00000658-199711000-00007
Autor:
Fred T. Lee, Dona Alberti, Jennifer Volkman, James P. Thomas, Luz Hammershaimb, Jill M. Kolesar, David M. King, Jianliang Zhang, Douglas G. McNeel, George Wilding, Andreas Friedl, James A. Zwiebel, Rebecca Marnocha, Jens C. Eickhoff
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 11(21)
At present, a variety of agents targeting tumor angiogenesis are under clinical investigation as new therapies for patients with cancer. Overexpression of the αvβ3 integrin on tumor vasculature has been associated with an aggressive phenotype of se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::486c4804a591f8202dd40aef7dcc9730
https://pubmed.ncbi.nlm.nih.gov/16278408
https://pubmed.ncbi.nlm.nih.gov/16278408